PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 1568607

Colonoscopy and endoscopic therapy for delayed post-polypectomy hemorrhage.

D K Rex·B S Lewis·J D Waye
View original source ↗Export metadata ↓

Abstract

Nine consecutive patients in whom endoscopic management of delayed post-polypectomy hemorrhage was attempted are described. Each patient presented with active rectal bleeding 12 hours to 12 days after snare resection of a colon polyp. In each patient, repeat colonoscopy identified the bleeding site and various combinations of injection therapy, electrocautery, or thermal injury led to cessation of hemorrhage. No complications resulted from repeat colonoscopy and endoscopic therapy. Colonoscopy and endoscopic therapy is feasible, effective, and safe in selected patients with active delayed post-polypectomy hemorrhage.

Explore related subjects

Colonic PolypsColonoscopyElectrocoagulationEpinephrineFemaleGastrointestinal HemorrhageHumansMaleMiddle AgedPostoperative ComplicationsRectumTime FactorsJournal Article

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

D K Rex, B S Lewis, J D Waye. Colonoscopy and endoscopic therapy for delayed post-polypectomy hemorrhage.. https://doi.org/10.1016/s0016-5107(92)70376-9

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed1992

Sample size for studying intermediate endpoints within intervention trails or observational studies.

An intermediate endpoint is a biologic event or marker that is a precursor to a given health outcome. Examples of potential intermediate endpoints include serum cholesterol for coronary heart disease, endogenous steroid hormones for breast cancer, and CD4 count for acquired immunodeficiency syndrome. When one is studying a potential intermediate endpoint in the context of an intervention trial, five types of questions may be investigated: 1) Does the intervention affect the intermediate endpoint? 2) Is the intermediate endpoint associated with prognostic or risk factors? 3) Is the intermediate endpoint associated with the main outcome? 4) Is the intervention effect on the main outcome mediated by the intermediate endpoint? 5) Are the prognostic or risk factor effects mediated by the intermediate endpoint? In this paper, the authors show that each of these questions had different sample size requirements, and they illustrate their point with a discussion of an ancillary study of large bowel epithelial proliferation in the National Cancer Institute's Polyp Prevention Trial. The same methods may be used in an observational study, in which case questions 2, 3, and 5 are relevant. However, much larger numbers than those used in the Polyp Prevention Trial example will be required when the main outcome is rare.

Colonic Polyps↗